This year at the European Haematology Association in Stockholm (Sweden), the International Myeloma Foundation interviewed Professor Leleu and Professor Ludwig on behalf of Binding Site. These interviews are available for you to view as two short videos approximately 5 minutes each:

Professor Leleu discusses the importance of Freelite in Multiple Myeloma

Professor Leleu is an Associate Professor at Service des Maladies du Sang Hopital Huriez, CHRU in Lille, France.

What does this video tell you?

• Freelite is a reproducible and simple quantitative serum assay Freelite is a more sensitive method to monitor response to treatment than serum and urine electrophoretic methods
• You can detect residual disease in Multiple Myeloma patients using Freelite
• Freelite is accepted in many international guidelines which has enabled the inclusion of more patients into clinical trials

Professor Ludwig discusses the importance of monitoring with Hevylite in Multiple Myeloma

Professor Ludwig is the Head of Department of Medicine and Medical Oncology, as well as the Director of the Myeloma Reference Center at the Wilhelminen Hospital in Vienna, Austria.

What does Professor Ludwig discuss?

• Hevylite is a simple and easy serum test
• The Hevylite ratio tells you the relationship between the size of the malignant clone and the size of the normal plasma cells
• You can accurately assess small levels of paraprotein. Serum protein electrophoresis cannot distinguish between normal and abnormal protein at such low levels
• You can use Hevylite to detect residual disease and progressive disease earlier than conventional tests
• Suppression of the non-involved isotype could not be measured before the development of Hevylite this is of high prognostic significance